| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 525 | 2019 |
| LigBuilder 2: A Practical de Novo Drug Design Approach Y Yuan, J Pei, L Lai Journal of chemical information and modeling 51 (5), 1083-1091, 2011 | 227 | 2011 |
| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 225 | 2020 |
| PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics S Khan, Y He, X Zhang, Y Yuan, S Pu, Q Kong, G Zheng, D Zhou Oncogene 39 (26), 4909-4924, 2020 | 206 | 2020 |
| Binding site detection and druggability prediction of protein targets for structure-based drug design Y Yuan, J Pei, L Lai Current pharmaceutical design 19 (12), 2326-2333, 2013 | 199 | 2013 |
| Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors L Zhou, Y Liu, W Zhang, P Wei, C Huang, J Pei, Y Yuan, L Lai Journal of medicinal chemistry 49 (12), 3440-3443, 2006 | 173 | 2006 |
| Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach S Ni, Y Yuan, J Huang, X Mao, M Lv, J Zhu, X Shen, J Pei, L Lai, H Jiang, ... Journal of medicinal chemistry 52 (17), 5295-5298, 2009 | 121 | 2009 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 112 | 2021 |
| Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies Y He, S Khan, Z Huo, D Lv, X Zhang, X Liu, Y Yuan, R Hromas, M Xu, ... Journal of Hematology & Oncology 13, 1-24, 2020 | 98 | 2020 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 86 | 2020 |
| Improved prediction of blood–brain barrier permeability through machine learning with combined use of molecular property-based descriptors and fingerprints Y Yuan, F Zheng, CG Zhan The AAPS journal 20, 1-10, 2018 | 81 | 2018 |
| LigBuilder V3: A Multi-Target de novo Drug Design Approach Y Yuan, J Pei, L Lai Frontiers in chemistry 8, 142, 2020 | 75 | 2020 |
| De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy E Shang, Y Yuan, X Chen, Y Liu, J Pei, L Lai Journal of chemical information and modeling 54 (4), 1235-1241, 2014 | 68 | 2014 |
| Assays and technologies for developing proteolysis targeting chimera degraders X Liu, X Zhang, D Lv, Y Yuan, G Zheng, D Zhou Future Medicinal Chemistry 12 (12), 1155-1179, 2020 | 58 | 2020 |
| Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ... European journal of medicinal chemistry 199, 112397, 2020 | 54 | 2020 |
| Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter Y Yuan, X Huang, NM Midde, PM Quizon, WL Sun, J Zhu, CG Zhan ACS chemical neuroscience 6 (4), 658-665, 2015 | 53 | 2015 |
| Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new generation of anti-inflammatory drugs K Ding, Z Zhou, S Hou, Y Yuan, S Zhou, X Zheng, J Chen, C Loftin, ... Scientific reports 8 (1), 5205, 2018 | 50 | 2018 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of medicinal chemistry 64 (19), 14230-14246, 2021 | 40 | 2021 |
| Piperlongumine conjugates induce targeted protein degradation J Pei, Y Xiao, X Liu, W Hu, A Sobh, Y Yuan, S Zhou, N Hua, ... Cell chemical biology 30 (2), 203-213. e17, 2023 | 36 | 2023 |
| Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport NM Midde, Y Yuan, PM Quizon, WL Sun, X Huang, CG Zhan, J Zhu Journal of Neuroimmune Pharmacology 10, 122-135, 2015 | 33 | 2015 |
